HWM
VRTX icon

Hohimer Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hohimer Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Buy
1,530
+67
+5% +$29.7K 0.08% 191
2026
Q1 		$653K Sell
1,463
-1,788
-55% -$834K 0.08% 190
2025
Q4 		$1.47M Sell
3,251
-18
-0.6% -$7.76K 0.2% 119
2025
Q3 		$1.28M Buy
3,269
+1,146
+54% +$479K 0.18% 126
2025
Q2 		$945K Buy
2,123
+26
+1% +$12K 0.17% 112
2025
Q1 		$1.02M Sell
2,097
-195
-9% -$90.9K 0.2% 106
2024
Q4 		$923K Sell
2,292
-28
-1% -$13K 0.17% 118
2024
Q3 		$1.08M Buy
2,320
+70
+3% +$33.6K 0.23% 111
2024
Q2 		$1.05M Sell
2,250
-633
-22% -$275K 0.24% 111
2024
Q1 		$1.21M Sell
2,883
-49
-2% -$20.7K 0.28% 96
2023
Q4 		$1.19M Buy
2,932
+24
+0.8% +$8.87K 0.3% 93
2023
Q3 		$1.01M Buy
2,908
+31
+1% +$10.8K 0.29% 95
2023
Q2 		$1.01M Sell
2,877
-76
-3% -$25.6K 0.28% 95
2023
Q1 		$930K Sell
2,953
-54
-2% -$16.2K 0.27% 94
2022
Q4 		$868K Sell
3,007
-19
-0.6% -$5.79K 0.28% 75
2022
Q3 		$876K Sell
3,026
-4
-0.1% -$1.15K 0.28% 93
2022
Q2 		$854K Sell
3,030
-3,275
-52% -$877K 0.25% 112
2022
Q1 		$1.65M Buy
6,305
+581
+10% +$138K 0.32% 93
2021
Q4 		$1.26M Sell
5,724
-211
-4% -$41K 0.26% 109
2021
Q3 		$1.08M Buy
5,935
+146
+3% +$28.5K 0.23% 116
2021
Q2 		$1.17M Buy
5,789
+2,859
+98% +$598K 0.24% 115
2021
Q1 		$630K Sell
2,930
-2,533
-46% -$556K 0.15% 131
2020
Q4 		$1.29M Sell
5,463
-33
-0.6% -$7.57K 0.34% 95
2020
Q3 		$1.21M Buy
5,496
+89
+2% +$24.6K 0.35% 97
2020
Q2 		$1.57M Sell
5,407
-401
-7% -$109K 0.54% 67
2020
Q1 		$1.56M Sell
5,808
-2,086
-26% -$479K 0.66% 62
2019
Q4 		$1.73M Buy
+7,894
New +$1.6M 0.6% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hohimer Wealth Management's VRTX Position: Q2 2026 in Review

Hohimer Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q2 2026, buying an estimated $29.7K and bringing the position to 1,530 shares worth $760K. The position accounts for 0.08% of the portfolio, ranked #191.

Hohimer Wealth Management first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.73M in Q4 2019. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Hohimer Wealth Management held 1,530 shares of Vertex Pharmaceuticals worth $760K as of Q2 2026.
  • Hohimer Wealth Management bought 67 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.7K.
  • Vertex Pharmaceuticals made up 0.08% of Hohimer Wealth Management's portfolio in Q2 2026, its #191 holding.
  • Hohimer Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Hohimer Wealth Management's Vertex Pharmaceuticals position peaked at $1.73M in Q4 2019.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.